Keywords: noven, vivelle, cleared, osteoporosis, prevention, novogyne, pharmaceuticals
Noven's Vivelle cleared for osteoporosis prevention
Article | 23 August 2000
Novogyne Pharmaceuticals, a joint venture company between NovenPharmaceuticals and Novartis, has received approval from the US Food and Drug Administration ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
